Comparative Pharmacology
Head-to-head clinical analysis: INCRUSE ELLIPTA versus ULSPIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCRUSE ELLIPTA versus ULSPIRA.
INCRUSE ELLIPTA vs ULSPIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Umeclidinium is a long-acting muscarinic antagonist (LAMA). It competitively inhibits M3 muscarinic receptors in the airways, reducing acetylcholine-induced bronchoconstriction and mucus secretion.
ULSPIRA (bosutinib) is a tyrosine kinase inhibitor that inhibits BCR-ABL kinase, leading to inhibition of proliferation and induction of apoptosis in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells.
Inhalation: 1 inhalation (62.5 mcg umeclidinium) once daily.
400 mg subcutaneously once daily; after 8 weeks, reduce to 200 mg subcutaneously once daily if serum phosphorus normalized.
None Documented
None Documented
Terminal elimination half-life is approximately 11 hours (range 10–13 hours) after inhalation, supporting once-daily dosing.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Umeclidinium is eliminated primarily by hepatic metabolism and biliary excretion; after oral administration, approximately 58% of the dose is excreted in feces (mostly as parent drug) and about 22% in urine. Renal excretion of unchanged drug is minimal (<1%).
Primarily renal (65-75% unchanged), with biliary/fecal excretion accounting for 20-30%.
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator